Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hans Briem
Observed names:
Briem, H.,
Briem, Hans,
H. BRIEM,
H. Briem,
HANS BRIEM
Institution:
Bayer (Germany)
Observed institutions:
Boehringer Ingelheim (Germany),
University of California, San Francisco,
Friedrich-Alexander-Universität Erlangen-Nürnberg,
ETH Zurich,
Max Planck Institute of Molecular Physiology,
Bayer (Germany),
Freie Universität Berlin
show all 7
ORCID:
0000-0002-8498-2448
Observed ORCID:
0000-0002-8498-2448
OpenAlex ID:
A5039089017
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
2019
·
Roman C. Hillig
, Brice Sautier
, et al.
·
Proceedings of the National Academy of Sciences
·
386
PDF
Efficient multi-objective molecular optimization in a continuous latent space
2019
·
Robin Winter
, Floriane Montanari
, et al.
·
Chemical Science
·
274
PDF
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
2017
·
Ulrich Lücking
, Arne Scholz
, et al.
·
ChemMedChem
·
196
PDF
The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer
2013
·
Ulrich Lücking
, Rolf Jautelat
, et al.
·
ChemMedChem
·
186
Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function
2011
·
Nadine Schneider
, Sally Hindle
, et al.
·
Journal of Computer-Aided Molecular Design
·
154
Molecular Similarity Based on DOCK-Generated Fingerprints
1996
·
Hans Briem
, Irwin D. Kuntz
·
Journal of Medicinal Chemistry
·
113
Multiple-Conformation and Protonation-State Representation in 4D-QSAR: The Neurokinin-1 Receptor System
2000
·
Angelo Vedani
, Hans Briem
, et al.
·
Journal of Medicinal Chemistry
·
93
Binding Kinetics Survey of the Drugged Kinome
2018
·
Victoria Georgi
, Felix Schiele
, et al.
·
Journal of the American Chemical Society
·
89
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
2020
·
Ulrich Lücking
, Lars Wortmann
, et al.
·
Journal of Medicinal Chemistry
·
86
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
2021
·
Ulrich Lücking
, Dirk Kosemund
, et al.
·
Journal of Medicinal Chemistry
·
85
From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors
2005
·
Rolf Jautelat
, Thomas Brumby
, et al.
·
ChemBioChem
·
82
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
2018
·
Gerhard Siemeister
, Anne Mengel
, et al.
·
Clinical Cancer Research
·
75
Facing the Challenges of Structure-Based Target Prediction by Inverse Virtual Screening
2014
·
Karen T. Schomburg
, Stefan Bietz
, et al.
·
Journal of Chemical Information and Modeling
·
72
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase
2020
·
Volker K. Schulze
, Ulrich Klar
, et al.
·
Journal of Medicinal Chemistry
·
60
Efficient Multi-Objective Molecular Optimization in a Continuous Latent Space
2019
·
Robin Winter
, Floriane Montanari
, et al.
·
ChemRxiv
·
56
An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer — against all odds?
2018
·
Markus Follmann
, Hans Briem
, et al.
·
Drug Discovery Today
·
56
PDF
Classifying “Kinase Inhibitor‐Likeness” by Using Machine‐Learning Methods
2005
·
Hans Briem
, Judith Günther
·
ChemBioChem
·
54
Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF‐R Inhibitors with Potent Antiproliferative Activities
2006
·
Ulrich Lücking
, Gerhard Siemeister
, et al.
·
ChemMedChem
·
50
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
2021
·
Clara Lemos
, Volker K. Schulze
, et al.
·
Cellular Oncology
·
48
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
2019
·
Julien Lefranc
, Volker Klaus Schulze
, et al.
·
Journal of Medicinal Chemistry
·
48
In vitro and in silico affinity fingerprints: Finding similarities beyond structural classes
2000
·
Hans Briem
, Uta F. Lessel
·
Perspectives in Drug Discovery and Design
·
46
Prioritizing Small Sets of Molecules for Synthesis through in‐silico Tools: A Comparison of Common Ranking Methods
2022
·
Marko Breznik
, Yunhui Ge
, et al.
·
ChemMedChem
·
44
PDF
Flexsim-X: A Method for the Detection of Molecules with Similar Biological Activity
2000
·
Uta F. Lessel
, Hans Briem
·
Journal of Chemical Information and Computer Sciences
·
39
Computational Macrocyclization: From de novo Macrocycle Generation to Binding Affinity Estimation
2017
·
Vincent Wagner
, Linda Jantz
, et al.
·
ChemMedChem
·
34
PDF
Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops
2017
·
Ulrich T. Luecking
, Arne Scholz
, et al.
·
Cancer Research
·
33
Show more works
View as search
Works count:
94
Citation count:
2,788
H-index:
29
I10-index:
37
Year
Topic
Type
